(DNLI) Denali Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US24823R1059
DNLI: Enzyme Replacement Therapies, Small Molecule Inhibitors, Gene Expression Modulators
Denali Therapeutics Inc. (NASDAQ: DNLI) is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative and lysosomal storage diseases. Their core technology revolves around a proprietary Transport Vehicle (TV) platform, which enables the delivery of therapeutic molecules across the blood-brain barrier—a major challenge in treating CNS disorders.
The companys pipeline includes multiple TV-enabled programs. DNL310 targets MPS II, a rare lysosomal storage disorder, using an enzyme replacement therapy approach. TAK-594/DNL593, currently in Phase 1/2 trials, addresses frontotemporal dementia linked to granulin mutations. Other notable programs include DNL126 for MPS IIIA (Sanfilippo Syndrome A) and DNL622 for MPS I (Hurler Syndrome). They also have earlier-stage programs targeting amyloid beta and HER2.
Denalis small molecule portfolio includes BIIB122/DNL151, an LRRK2 inhibitor for Parkinsons disease, and SAR443820/DNL788, a RIPK1 inhibitor for CNS diseases. They also have DNL343, an eIF2B activator for amyotrophic lateral sclerosis, and SAR443122/DNL758, another RIPK1 inhibitor for peripheral inflammatory conditions.
Collaborations are a key part of their strategy. Partnerships with Biogen, Genzyme, Takeda, F-star, and Genentech underscore their commitment to advancing their pipeline. These partnerships not only validate their technology but also provide resources to accelerate development.
Denali has a $3 billion market capitalization, reflecting investor confidence in their approach. While they are currently pre-revenue, their high P/S ratio highlights the markets expectation of future growth. The company, renamed from SPR Pharma in 2015, operates from South San Francisco, a hub for biotech innovation.
Investors should note that Denalis success hinges on their ability to navigate clinical trials and secure approvals. Their TV platforms versatility positions them well in both rare and neurodegenerative diseases. For more details, visit their website: https://www.denalitherapeutics.com.
Additional Sources for DNLI Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
DNLI Stock Overview
Market Cap in USD | 3,005m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2017-12-08 |
DNLI Stock Ratings
Growth 5y | -13.5% |
Fundamental | -53.9% |
Dividend | 0.0% |
Rel. Strength Industry | 33.1 |
Analysts | 4.67/5 |
Fair Price Momentum | 18.63 USD |
Fair Price DCF | - |
DNLI Dividends
No Dividends PaidDNLI Growth Ratios
Growth Correlation 3m | -57.7% |
Growth Correlation 12m | 56.4% |
Growth Correlation 5y | -54.2% |
CAGR 5y | -2.28% |
CAGR/Mean DD 5y | -0.04 |
Sharpe Ratio 12m | 0.62 |
Alpha | -24.44 |
Beta | 2.45 |
Volatility | 58.82% |
Current Volume | 730.5k |
Average Volume 20d | 872.3k |
As of February 19, 2025, the stock is trading at USD 21.79 with a total of 730,468 shares traded.
Over the past week, the price has changed by +5.88%, over one month by -5.43%, over three months by -9.88% and over the past year by +31.74%.
No, based on ValueRay Fundamental Analyses, Denali Therapeutics (NASDAQ:DNLI) is currently (February 2025) a stock to sell. It has a ValueRay Fundamental Rating of -53.90 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DNLI as of February 2025 is 18.63. This means that DNLI is currently overvalued and has a potential downside of -14.5%.
Denali Therapeutics has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy DNLI.
- Strong Buy: 13
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, DNLI Denali Therapeutics will be worth about 22.4 in February 2026. The stock is currently trading at 21.79. This means that the stock has a potential upside of +2.62%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 40 | 83.6% |
Analysts Target Price | 39.7 | 82.3% |
ValueRay Target Price | 22.4 | 2.6% |